Biblio

Author Title Type [ Year

]

Filters: Author is Kim, Yoo-Jin [Clear All Filters]

2024

Park S, Bang S-Y, Kwag D, Lee JHyuk, Kim TYoon, Lee J, Min GJune, Park SSoo, Yahng S-A, Jeon Y-W, et al. Reduced toxicity (FluBu3) versus myeloablative (BuCy) conditioning in acute myeloid leukemia patients who received first allogeneic hematopoietic stem cell transplantation in measurable residual disease-negative CR1. Bone Marrow Transplant. 2024.

2023

Jeon Y, Kim T-Y, Min GJune, Park S-S, Park S, Yoon J-H, Lee S-E, Cho B-S, Eom K-S, Kim Y-J, et al. Efficacy of ex vivo purging with CD34+ selection to maximize the effects of autologous stem cell transplantation in peripheral T-cell lymphoma patients. Cytotherapy. 2023.

Lim JUk, Park S, Yoon J-H, Lee S-E, Cho B-S, Kim Y-J, Lee S, Kim H-J, Rhee CKook. Efficacy of inhaled tiotropium add-on to budesonide/formoterol in patients with bronchiolitis obliterans developing after hematopoietic stem cell transplantation. Respir Med. 2023:107410.

Min G-J, Jeon Y-W, Kim TYoon, Kwag D, Kim B-S, Lee J, Lee JHyuk, Park S-S, Park S, Yoon J-H, et al. The salvage role of allogeneic hematopoietic stem-cell transplantation in relapsed/refractory diffuse large B cell lymphoma. Sci Rep. 2023;13(1):17496.

2022

Kwag D, Cho B-S, Bang S-Y, Lee JHyuk, Min G-J, Park S-S, Park S, Yoon J-H, Lee S-E, Eom K-S, et al. Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis. Blood Cancer J. 2022;12(12):169.

2021

Cho B-S, Yahng S-A, Min G-J, Park S, Park S-S, Shin S-H, Jeon Y-W, Yoon J-H, Lee S-E, Eom K-S, et al. Comparable outcomes after alternative and matched sibling donor hematopoietic stem cell transplantation and the role of molecular measurable residual disease for acute myeloid leukemia in elderly patients. Transplant Cell Ther. 2021.

2020

Park S, Min GJune, Park SSoo, Yahng S-A, Jeon Y-W, Shin S-H, Yoon J-H, Lee S-E, Cho BSik, Eom K-S, et al. Comparison of myeloablative (CyTBI, BuCy) versus reduced-intensity (FluBu2TBI400) peripheral blood stem cell transplantation in acute myeloid leukemia patients with pre-transplant low WT1 expression. Biol Blood Marrow Transplant. 2020.

Shin S-H, Park S-S, Park S, Jeon Y-W, Yoon J-H, Yahng S-A, Cho B-S, Kim Y-J, Lee S, Kim H-J, et al. Nonmyeloablative matched sibling stem cell transplantation with the optional reinforced stem cell infusion for patients with hemoglobinopathies. Eur J Haematol. 2020.

Lee S-E, Min GJune, Park S-S, Park S, Yoon J-H, Shin SHwan, Cho B-S, Eom K-S, Kim Y-J, Lee S, et al. Outcomes of haploidentical stem cell transplantation using total body irradiation (600 cGy) and fludarabine with ATG in adult patients with severe aplastic anemia: A prospective phase II study. Biol Blood Marrow Transplant. 2020.

2019

Lee S-E, Lim J-Y, Bin Ryu D-, Kim TWoo, Park SSoo, Jeon Y-W, Yoon J-H, Cho B-S, Eom K-S, Kim Y-J, et al. Alteration of the intestinal microbiota by broad-spectrum antibiotic use correlates with the occurrence of intestinal graft-versus-host disease. Biol Blood Marrow Transplant. 2019.

Cho B-S, Jeon Y-W, Hahn A-R, Lee T-H, Park S-S, Yoon J-H, Lee S-E, Eom K-S, Kim Y-J, Lee S, et al. Improved survival outcomes and restoration of graft-vs-leukemia effect by deferasirox after allogeneic stem cell transplantation in acute myeloid leukemia. Cancer Med. 2019.

Cho B-S, Min G-J, Park S-S, Shin S-H, Yahng S-A, Jeon Y-W, Yoon J-H, Lee S-E, Eom K-S, Kim Y-J, et al. WT1 measurable residual disease assay in AML who underwent allogeneic hematopoietic stem cell transplantation; optimal time points, threshold, and candidates. Biol Blood Marrow Transplant. 2019.

2018

Park S-S, Jeon Y-W, Min GJune, Park S, Yahng S-A, Yoon J-H, Shin S-H, Lee S-E, Cho B-S, Eom K-S, et al. Graft-versus-host disease free, relapse-free survival after allogeneic stem cell transplantation for myelodysplastic syndrome. Biol Blood Marrow Transplant. 2018.

2014

Choi MHyung, Jung JIm, Chung WDo, Kim Y-J, Lee S-E, Han DHee, Ahn MIm, Park SHee. Acute Pulmonary Complications in Patients with Hematologic Malignancies. Radiographics. 2014;34(6):1755-1768.

Lee S-E, Yoon J-H, Shin S-H, Eom K-S, Kim Y-J, Kim H-J, Lee S, Cho S-G, Lee JWook, Min W-S, et al. Bone Marrow Plasma Cell Assessment before Peripheral Blood Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Biomed Res Int. 2014;2014:982504.

2013

Yahng S-A, Yoon J-H, Shin S-H, Lee S-E, Eom K-S, Kim Y-J. Acute colonic pseudo-obstruction following allogeneic stem cell transplantation successfully treated by neostigmine. Blood Res. 2013;48(2):145-8.

Eom K-S, Shin S-H, Yoon J-H, Yahng S-A, Lee S-E, Cho B-S, Kim Y-J, Kim H-J, Min C-K, Kim D-W, et al. Comparable long-term outcomes after reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for adult high-risk acute lymphoblastic leukemia in complete remission. Am J Hematol. 2013.

Min C-K, Lee S-E, Yahng S-A, Cho B-S, Eom K-S, Kim Y-J, Kim H-J, Lee S, Cho S-G, Kim D-W, et al. The impact of novel therapeutic agents before and after frontline autologous stem cell transplantation in patients with multiple myeloma. Blood Res. 2013;48(3):198-205.

Yoon J-H, Kim H-J, Shin S-H, Yahng S-A, Cho B-S, Eom K-S, Kim Y-J, Lee S, Min C-K, Cho S-G, et al. Normal karyotype mosaicism in adult AML patients with adverse-risk and undefined karyotype: preliminary report of treatment outcomes after hematopoietic stem cell transplantation. Int J Hematol. 2013.

Kim Y-J, Jang JHo, Kwak J-Y, Lee J-H, Kim H-J. Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations. Blood Res. 2013;48(2):87-98.